Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

[1]  Robin L. Jones,et al.  The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib , 2019, Expert review of anticancer therapy.

[2]  M. Lim,et al.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Borg,et al.  Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? , 2015, Journal of thoracic disease.

[4]  Huilin Yang,et al.  Inflammatory myofibroblastic tumor of the thigh without bone involvement: a case report , 2014, World Journal of Surgical Oncology.

[5]  J. Reith,et al.  An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor , 2014, Case reports in pathology.

[6]  P. Stephens,et al.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.

[7]  A. Lespagnol,et al.  Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[9]  K. Prabhash,et al.  Crizotinib: A comprehensive review , 2013, South Asian journal of cancer.

[10]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[11]  Z. Tothova,et al.  Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors , 2012, Current opinion in oncology.

[12]  Y. Bang,et al.  The potential for crizotinib in non-small cell lung cancer: a perspective review , 2011, Therapeutic advances in medical oncology.

[13]  G. Shapiro,et al.  Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.

[14]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[15]  R. Kumar,et al.  Inflammatory myofibroblastic tumour , 2010, European Respiratory Journal.

[16]  J. Hornick,et al.  Inflammatory myofibroblastic tumours: where are we now? , 2007, Journal of Clinical Pathology.

[17]  D. Felsher,et al.  Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy , 2007, Cancer biology & therapy.

[18]  C. Fletcher,et al.  Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.

[19]  F. Mertens,et al.  Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor , 2006, International journal of cancer.

[20]  P. Marynen,et al.  ALK‐ATIC fusion in urinary bladder inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[21]  M. Lovell,et al.  Recurrent inflammatory pseudotumors in children. , 2003, Journal of pediatric surgery.

[22]  P. Marynen,et al.  Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor , 2002, Genes, chromosomes & cancer.

[23]  M. Ladanyi,et al.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. , 2001, The American journal of pathology.

[24]  M. Ladanyi.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. , 2000, The American journal of pathology.

[25]  C. Griffin,et al.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. , 1999, Cancer research.